DK0789591T3 - Fremgangsmåde til identifikation af individer, som lider af en celleabnormitet - Google Patents
Fremgangsmåde til identifikation af individer, som lider af en celleabnormitetInfo
- Publication number
- DK0789591T3 DK0789591T3 DK95913476T DK95913476T DK0789591T3 DK 0789591 T3 DK0789591 T3 DK 0789591T3 DK 95913476 T DK95913476 T DK 95913476T DK 95913476 T DK95913476 T DK 95913476T DK 0789591 T3 DK0789591 T3 DK 0789591T3
- Authority
- DK
- Denmark
- Prior art keywords
- individuals suffering
- identifying individuals
- cell abnormality
- abnormality
- cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/195,186 US5558995A (en) | 1993-01-22 | 1994-02-14 | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
| US08/196,630 US5683886A (en) | 1993-06-17 | 1994-02-15 | Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof |
| US08/292,492 US6328971B1 (en) | 1993-01-22 | 1994-08-18 | MAGE-1 derived nona peptides, and compositions thereof |
| PCT/US1995/001446 WO1995021630A1 (en) | 1994-02-14 | 1995-01-26 | Methods for identifying individuals suffering from a cellular abnormality |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0789591T3 true DK0789591T3 (da) | 2003-05-19 |
Family
ID=27393408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95913476T DK0789591T3 (da) | 1994-02-14 | 1995-01-26 | Fremgangsmåde til identifikation af individer, som lider af en celleabnormitet |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6328971B1 (da) |
| EP (1) | EP0789591B1 (da) |
| JP (1) | JP2002502224A (da) |
| AT (1) | ATE237685T1 (da) |
| AU (1) | AU697246B2 (da) |
| CA (1) | CA2182969A1 (da) |
| DE (1) | DE69530410T2 (da) |
| DK (1) | DK0789591T3 (da) |
| ES (1) | ES2197196T3 (da) |
| FI (1) | FI963170A0 (da) |
| NO (1) | NO963347L (da) |
| NZ (1) | NZ282938A (da) |
| PT (1) | PT789591E (da) |
| WO (1) | WO1995021630A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877017A (en) * | 1993-06-17 | 1999-03-02 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof |
| US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
| US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| WO2002044723A2 (en) * | 2000-11-28 | 2002-06-06 | Eileen Louise Rice Mcfarland | Method for diagnosing a predisposition of psychosis in a progeny |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066783A (en) * | 1986-05-20 | 1991-11-19 | Cohen Eric A | Antiviral peptides and means for treating herpes infections |
| WO1992013069A1 (en) * | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5558995A (en) * | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
| AU680236B2 (en) * | 1993-01-22 | 1997-07-24 | Ludwig Institute For Cancer Research | Method for identifying and treating individuals bearing cancer cells that express HLA-C-Clone 10/MAGE-1 |
| CN1118572A (zh) * | 1993-03-05 | 1996-03-13 | 萨依特尔有限公司 | Hla-a2.1组合肽及其用途 |
| US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
| AU690371B2 (en) * | 1994-09-30 | 1998-04-23 | Ludwig Institute For Cancer Research | Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor |
-
1994
- 1994-08-18 US US08/292,492 patent/US6328971B1/en not_active Expired - Lifetime
-
1995
- 1995-01-26 FI FI963170A patent/FI963170A0/fi unknown
- 1995-01-26 EP EP95913476A patent/EP0789591B1/en not_active Expired - Lifetime
- 1995-01-26 CA CA002182969A patent/CA2182969A1/en not_active Abandoned
- 1995-01-26 DE DE69530410T patent/DE69530410T2/de not_active Expired - Lifetime
- 1995-01-26 AU AU20899/95A patent/AU697246B2/en not_active Ceased
- 1995-01-26 WO PCT/US1995/001446 patent/WO1995021630A1/en not_active Ceased
- 1995-01-26 DK DK95913476T patent/DK0789591T3/da active
- 1995-01-26 JP JP52127195A patent/JP2002502224A/ja not_active Ceased
- 1995-01-26 ES ES95913476T patent/ES2197196T3/es not_active Expired - Lifetime
- 1995-01-26 AT AT95913476T patent/ATE237685T1/de active
- 1995-01-26 NZ NZ282938A patent/NZ282938A/xx unknown
- 1995-01-26 PT PT95913476T patent/PT789591E/pt unknown
-
1996
- 1996-08-12 NO NO963347A patent/NO963347L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI963170L (fi) | 1996-08-13 |
| AU697246B2 (en) | 1998-10-01 |
| EP0789591A4 (en) | 1998-07-01 |
| EP0789591A1 (en) | 1997-08-20 |
| JP2002502224A (ja) | 2002-01-22 |
| NZ282938A (en) | 2000-01-28 |
| EP0789591B1 (en) | 2003-04-16 |
| US6328971B1 (en) | 2001-12-11 |
| FI963170A7 (fi) | 1996-08-13 |
| WO1995021630A1 (en) | 1995-08-17 |
| NO963347L (no) | 1996-08-14 |
| AU2089995A (en) | 1995-08-29 |
| ES2197196T3 (es) | 2004-01-01 |
| DE69530410D1 (de) | 2003-05-22 |
| DE69530410T2 (de) | 2004-03-25 |
| NO963347D0 (no) | 1996-08-12 |
| CA2182969A1 (en) | 1995-08-17 |
| PT789591E (pt) | 2003-08-29 |
| FI963170A0 (fi) | 1996-08-13 |
| ATE237685T1 (de) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207775A (pt) | Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização | |
| PT1091975E (pt) | Nova ciclosporina com um perfil de actividade melhorado | |
| HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
| WO1999051748A3 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| FI971610A7 (fi) | Menetelmä syklisten depsipeptidien sulfonyloimiseksi, sulfenyloimiseks i, ja fosforyloimiseksi | |
| DK0851784T3 (da) | Blodbehandlingssystemer og fremgangsmåder til opsamling af mononukleare celler | |
| EP1102988B8 (de) | Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür | |
| DE69510336D1 (de) | Verfahren zur diagnose von praeklampsie | |
| AU2003217652A8 (en) | Methods for continuous performance testing | |
| NO952385L (no) | Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen | |
| DE60026150D1 (de) | Diagnostika und therapeutika für osteoporose | |
| DK0789591T3 (da) | Fremgangsmåde til identifikation af individer, som lider af en celleabnormitet | |
| DK1179183T3 (da) | Fremgangsmåde til identifikation af præneoplastiske og/eller neoplastiske tilstande hos pattedyr | |
| NO963487L (no) | Isolerte, tyrosinaseavledete peptider, samt anvendelser derav | |
| ATE250130T1 (de) | Gereinigte telomerase | |
| IT1292884B1 (it) | Metodo per la sterilizzazione a freddo di un forno per impiego farmaceutico e forno che realizza tale metodo. | |
| ATE390440T1 (de) | Neuroaktive peptide | |
| WO1999021994A3 (en) | Human vesicle membrane protein-like proteins | |
| DK1039931T3 (da) | Multivalente rekombinante antistoffer til at behandle HRV infektioner | |
| TR200100175T2 (tr) | Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler. | |
| WO2000024911A3 (en) | Human phospholipases | |
| ES2122912A1 (es) | Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales. | |
| IT1293214B1 (it) | Metodo per la fabbricazione di membrane, in particolare per membrane di regolazione di apparecchi respiratori. | |
| WO2001033220A3 (en) | The use of the area postreama to identify therapeutic compounds | |
| WO2000014248A8 (en) | Cyclic nucleotide-associated proteins |